Clinical Trial Update: A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nimotuzumab added to concurrent chemoradiotherapy with sequential maintenance for cervical cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Biotech Pharmaceutical Co., Ltd. | Conditions: Cervical Cancer | Phase 3 | Status: NOT_YET_RECRUITING